CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 170 filers reported holding CLOVIS ONCOLOGY INC in Q4 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,461,000 | -3.9% | 533,832 | 0.0% | 0.02% | 0.0% |
| Q4 2020 | $2,562,000 | -68.3% | 533,832 | -61.5% | 0.02% | -73.7% |
| Q3 2020 | $8,077,000 | -7.8% | 1,385,635 | +6.7% | 0.08% | -18.3% |
| Q2 2020 | $8,765,000 | -14.0% | 1,298,450 | +29.9% | 0.09% | -17.7% |
| Q1 2020 | $10,189,000 | -2.2% | 999,915 | +0.0% | 0.11% | +0.9% |
| Q4 2019 | $10,423,000 | +134.5% | 999,853 | -11.6% | 0.11% | +89.8% |
| Q3 2019 | $4,445,000 | -72.9% | 1,131,123 | +2.1% | 0.06% | -71.2% |
| Q2 2019 | $16,405,000 | -15.4% | 1,108,123 | +41.8% | 0.20% | -17.3% |
| Q1 2019 | $19,401,000 | +268.6% | 781,623 | +166.7% | 0.25% | +206.2% |
| Q4 2018 | $5,264,000 | -17.4% | 293,100 | +35.0% | 0.08% | -4.7% |
| Q3 2018 | $6,376,000 | -28.5% | 217,100 | +10.8% | 0.08% | -39.7% |
| Q2 2018 | $8,913,000 | -3.3% | 196,000 | +12.3% | 0.14% | -10.2% |
| Q1 2018 | $9,214,000 | -22.3% | 174,500 | 0.0% | 0.16% | -23.4% |
| Q4 2017 | $11,866,000 | -33.8% | 174,500 | -19.8% | 0.20% | -34.5% |
| Q3 2017 | $17,922,000 | +13.3% | 217,500 | +28.7% | 0.31% | +5.4% |
| Q2 2017 | $15,824,000 | +107.1% | 169,000 | +40.8% | 0.30% | +100.7% |
| Q1 2017 | $7,641,000 | +31.3% | 120,000 | -8.4% | 0.15% | +10.4% |
| Q4 2016 | $5,819,000 | +8.3% | 131,000 | -12.1% | 0.13% | +3.9% |
| Q3 2016 | $5,371,000 | +732.7% | 149,000 | +217.0% | 0.13% | +658.8% |
| Q2 2016 | $645,000 | +5.6% | 47,000 | +46.9% | 0.02% | +13.3% |
| Q1 2016 | $611,000 | -51.9% | 32,000 | -11.8% | 0.02% | -55.9% |
| Q4 2015 | $1,271,000 | -67.7% | 36,300 | -15.2% | 0.03% | -64.9% |
| Q3 2015 | $3,936,000 | -25.4% | 42,800 | -28.7% | 0.10% | -11.8% |
| Q2 2015 | $5,273,000 | +1.5% | 60,000 | -14.3% | 0.11% | +4.8% |
| Q1 2015 | $5,197,000 | -14.9% | 70,000 | -35.8% | 0.10% | -18.0% |
| Q4 2014 | $6,104,000 | – | 109,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |